GAITHERSBURG, Md. , Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:

• Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
• Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M^® adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visit novavax.com and LinkedIn for more information.

Contacts: 

Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com

Media
Yvonne Sprow
844-264-8571
media@novavax.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026-302692051.html

SOURCE Novavax, Inc.